Carbapenems are a class of beta-lactam antibiotic that are active against many aerobic and anaerobic gram-positive and gram-negative organisms. Thienamycin was the first carbapenem to be discovered in 1976. Carbapenems are notable for their ability to inhibit beta-lactamase enzymes (also called penicillinase) - a type of enzyme that greatly reduces the activity of antibiotics such as penicillins and cephamycins. Of all the beta-lactam antibiotics, carbapenems possess the broadest spectrum of activity and the greatest potency against bacteria. Because of this, they are often reserved for more severe infections or used as "last-line" agents.
Carbapenems inhibit bacterial cell wall synthesis by binding to the penicillin-binding proteins and interfering with cell wall formation.
Name | Updated |
---|---|
Meropenem (Meropenem [ mer-oh-peh-nem ]) | 11-Aug-2023 |
Imipenem and cilastatin (Imipenem and cilastatin [ im-i-pen-em-and-sye-la-stat-in ]) | 11-Aug-2023 |
Doribax (Doripenem [ dor-i-pen-em ]) | 05-Aug-2023 |
Primaxin iv (Imipenem and cilastatin [ im-i-pen-em-and-sye-la-stat-in ]) | 14-Jul-2023 |
Merrem (Meropenem [ mer-oh-peh-nem ]) | 13-Jul-2023 |
Invanz (Ertapenem [ er-ta-pen-em ]) | 13-Jul-2023 |
Ertapenem (Ertapenem [ er-ta-pen-em ]) | 10-Jul-2023 |